POS-01.123: Treatment of voiding dysfunction in patients with multiple sclerosis by injection of botulinum-A toxin (BTX-A) in external sphincter

Urology ◽  
2007 ◽  
Vol 70 (3) ◽  
pp. 228
Author(s):  
M.A. Mohamadzadeh Rezaei ◽  
M. Foroghipoor
2006 ◽  
Vol 176 (1) ◽  
pp. 332-336 ◽  
Author(s):  
Zoran I. Radojicic ◽  
Sava V. Perovic ◽  
Natasa M. Milic

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Gino Vricella ◽  
Mary Campigotto ◽  
Douglas Coplen ◽  
Erica Traxel ◽  
Paul Austin

2011 ◽  
Vol 6 (3) ◽  
pp. 142-149 ◽  
Author(s):  
Sunshine Murray ◽  
Gary E. Lemack

2013 ◽  
Vol 7 (9-10) ◽  
pp. 181 ◽  
Author(s):  
Jacques Corcos

Patients with multiple sclerosis (MS) have a very high prevalence of lower urinary tract symptoms—as many as 90% of patients with MS experience some form of voiding dysfunction and/or incontinence.1 This summary provides a brief overview of MS epidemiology, pathophysiology, the impact of the disease on patient quality of life, and the particular kinds of urinary tract abnormalities and symptoms that can present among patients with MS. Strategies to help diminish the impact of these symptoms are also discussed.


BMC Urology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Fatemeh Nazari ◽  
Vahid Shaygannejad ◽  
Mehrdad Mohammadi Sichani ◽  
Marjan Mansourian ◽  
Valiollah Hajhashemi

Sign in / Sign up

Export Citation Format

Share Document